Physician profile
Aroti Hegde
NPI 1033164785
$21,650.64
in general payments reported to CMS, 2019-2025
19 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $151 · 2021: $6,882 · 2022: $157 · 2023: $353 · 2024: $13K · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,320 · Travel and Lodging: $4,600 · Food and Beverage: $1,015 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,320.00 |
| Travel and Lodging | $4,599.77 |
| Food and Beverage | $1,015.21 |
| Education | $102.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $19,875.83 | 2019-2024 | Aquadex Smartflow Console |
| Amgen INC. | $268.10 | 2019-2024 | Parsabiv, Aranesp, Tavneos |
| Astrazeneca Pharmaceuticals Lp | $184.04 | 2019-2025 | Farxiga |
| Akebia Therapeutics INC | $183.16 | 2019-2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $182.45 | 2022-2025 | |
| Vifor Pharma, INC. | $138.42 | 2019-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $116.61 | 2019-2025 | Velphoro, Velphoro |
| Abbvie INC. | $113.91 | 2024 | |
| Calliditas Therapeutics US INC. | $99.41 | 2023 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $97.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $80.32 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $65.38 | 2023-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $52.10 | 2019-2023 | Jynarque |
| Lilly USA, LLC | $43.52 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $38.08 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $33.55 | 2023 | Rayaldee |
| Ardelyx, INC. | $33.43 | 2024 | Ibsrela |
| Novo Nordisk INC | $27.15 | 2025 | Ozempic |
| Shire North American Group INC | $17.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aroti Hegde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.